Distinguishing features of long COVID identified through immune profiling

© 2023. The Author(s)..

Post-acute infection syndromes may develop after acute viral disease1. Infection with SARS-CoV-2 can result in the development of a post-acute infection syndrome known as long COVID. Individuals with long COVID frequently report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfunctions2-4. However, the biological processes that are associated with the development and persistence of these symptoms are unclear. Here 275 individuals with or without long COVID were enrolled in a cross-sectional study that included multidimensional immune phenotyping and unbiased machine learning methods to identify biological features associated with long COVID. Marked differences were noted in circulating myeloid and lymphocyte populations relative to the matched controls, as well as evidence of exaggerated humoral responses directed against SARS-CoV-2 among participants with long COVID. Furthermore, higher antibody responses directed against non-SARS-CoV-2 viral pathogens were observed among individuals with long COVID, particularly Epstein-Barr virus. Levels of soluble immune mediators and hormones varied among groups, with cortisol levels being lower among participants with long COVID. Integration of immune phenotyping data into unbiased machine learning models identified the key features that are most strongly associated with long COVID status. Collectively, these findings may help to guide future studies into the pathobiology of long COVID and help with developing relevant biomarkers.

Errataetall:

UpdateOf: medRxiv. 2022 Aug 10;:. - PMID 35982667

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:623

Enthalten in:

Nature - 623(2023), 7985 vom: 11. Nov., Seite 139-148

Sprache:

Englisch

Beteiligte Personen:

Klein, Jon [VerfasserIn]
Wood, Jamie [VerfasserIn]
Jaycox, Jillian R [VerfasserIn]
Dhodapkar, Rahul M [VerfasserIn]
Lu, Peiwen [VerfasserIn]
Gehlhausen, Jeff R [VerfasserIn]
Tabachnikova, Alexandra [VerfasserIn]
Greene, Kerrie [VerfasserIn]
Tabacof, Laura [VerfasserIn]
Malik, Amyn A [VerfasserIn]
Silva Monteiro, Valter [VerfasserIn]
Silva, Julio [VerfasserIn]
Kamath, Kathy [VerfasserIn]
Zhang, Minlu [VerfasserIn]
Dhal, Abhilash [VerfasserIn]
Ott, Isabel M [VerfasserIn]
Valle, Gabrielee [VerfasserIn]
Peña-Hernández, Mario [VerfasserIn]
Mao, Tianyang [VerfasserIn]
Bhattacharjee, Bornali [VerfasserIn]
Takahashi, Takehiro [VerfasserIn]
Lucas, Carolina [VerfasserIn]
Song, Eric [VerfasserIn]
McCarthy, Dayna [VerfasserIn]
Breyman, Erica [VerfasserIn]
Tosto-Mancuso, Jenna [VerfasserIn]
Dai, Yile [VerfasserIn]
Perotti, Emily [VerfasserIn]
Akduman, Koray [VerfasserIn]
Tzeng, Tiffany J [VerfasserIn]
Xu, Lan [VerfasserIn]
Geraghty, Anna C [VerfasserIn]
Monje, Michelle [VerfasserIn]
Yildirim, Inci [VerfasserIn]
Shon, John [VerfasserIn]
Medzhitov, Ruslan [VerfasserIn]
Lutchmansingh, Denyse [VerfasserIn]
Possick, Jennifer D [VerfasserIn]
Kaminski, Naftali [VerfasserIn]
Omer, Saad B [VerfasserIn]
Krumholz, Harlan M [VerfasserIn]
Guan, Leying [VerfasserIn]
Dela Cruz, Charles S [VerfasserIn]
van Dijk, David [VerfasserIn]
Ring, Aaron M [VerfasserIn]
Putrino, David [VerfasserIn]
Iwasaki, Akiko [VerfasserIn]

Links:

Volltext

Themen:

Antibodies, Viral
Biomarkers
Hydrocortisone
Journal Article
WI4X0X7BPJ

Anmerkungen:

Date Completed 03.11.2023

Date Revised 12.03.2024

published: Print-Electronic

UpdateOf: medRxiv. 2022 Aug 10;:. - PMID 35982667

Citation Status MEDLINE

doi:

10.1038/s41586-023-06651-y

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM362448949